Download PDF
Drug Res (Stuttg) 2016; 66(11): 614-616
DOI: 10.1055/s-0042-112366
Short Communication
© Georg Thieme Verlag KG Stuttgart · New York

Agomelatine and Transient Elevation of Creatine Phosphokinase

A. Zormann
1   Department of Psychiatry, University of Basel, Basel, Switzerland
,
J. Blum
1   Department of Psychiatry, University of Basel, Basel, Switzerland
,
C. Suenderhauf
2   Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
,
M. Vogel
1   Department of Psychiatry, University of Basel, Basel, Switzerland
,
A. Walter
1   Department of Psychiatry, University of Basel, Basel, Switzerland
› Author Affiliations
Further Information

Publication History

received 06 June 2016

accepted 08 July 2016

Publication Date:
09 August 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Agomelatine is an antidepressant drug with moderate agonistic action at the melatonine receptor MT1 and weak effect at MT2. According to clinical studies, agomelatine ameliorates depressive symptoms and improves sleep quality. Side effects such as elevated liver enzymes are well-known. Therefore, routine laboratory monitoring of liver function is recommended periodically throughout treatment because of a rare risk of more serious liver reactions. 2 patients with creatine phosphokinase elevation during treatment with agomelatine are presented. We recommend a check of the creatine phosphokinase level during the initial treatment phase in patients receiving agomelatine for the first time.

Key words

adverse drug reactions - antidepressant drugs - neuropharmacology - psychiatric disorders
 

  • References

  • 1 Srinivasan V, Zakaria R, Othman Z et al. Agomelatine in depressive disorders: its novel mechanisms of action. J Neuropsychiatry Clin Neurosci 2012; 24: 290-308
    CrossrefPubMedGoogle Scholar
  • 2 Pae CU. Agomelatine: A new option for treatment of depression?. Expert Opin Pharmacother 2014; 15: 443-447
    CrossrefPubMedGoogle Scholar
  • 3 Keks N, Hope J, Culhane C. Management of antidepressant-induced sexual dysfunction. Australas Psychiatry 2014; 22: 525-528
    CrossrefPubMedGoogle Scholar
  • 4 De Berardis D, Fornaro M, Serroni N et al. Agomelatine beyond borders: Current evidences of its efficacy in disorders other than major depression. Int J Mol Sci 2015; 16: 1111-1130
    CrossrefPubMedGoogle Scholar
  • 5 Shiovitz TM, Joo LS, Bailey Manlosa N et al. Extreme creatine phosphokinase elevation in a 20-year-old man participating in a clinical trial of major depressive disorder. J Clin Psychiatry 2008; 69: 1832-1834
    CrossrefPubMedGoogle Scholar
  • 6 Baird MF, Graham SM, Baker JS et al. Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery. J Nutr Metab. 2012
    PubMedGoogle Scholar
  • 7 Totsuka M, Nakaji S, Suzuki K et al. Break point of serum creatine kinase release after endurance exercise. J Appl Physiol 2002; 93: 1280-1286
    CrossrefPubMedGoogle Scholar
  • 8 Sayers SP, Clarkson PM. Short-term immobilization after eccentric exercise. Part II: Creatine kinase and myoglobin. Med Sci Sports Exerc 2003; 35: 762-768
    CrossrefPubMedGoogle Scholar
  • 9 Jullian-Desayes I, Roselli A, Lamy C et al. Rhabdomyolysis with acute renal failure and deep vein thrombosis induced by antipsychotic drugs: A case report. Pharmacopsychiatry 2015; 48: 265-267
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Lang FU, Lang S, Becker T et al. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology (Berl) 2015; 232: 1-5
    CrossrefPubMedGoogle Scholar